In recent years, expanded criteria have integrated tumor markers (e.g., alpha-fetoprotein [AFP], protein induced by vitamin K absence or antagonist-II [PIVKA II]), growth rates, response rates to locoregional treatments, and artificial intelligence (AI) tools to improve post-LT outcomes and patient selection [2–4]. This evidence concerns the gene AFP and neoplasm.